上海佑希创医药科技有限公司

Shanghai Youxichuang Pharmaceutical Technology Co., Ltd. is a Chinese biotechnology company founded in 2024 as a wholly-owned subsidiary of Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SH). The company focuses on the research and development of innovative oncology therapeutics, leveraging its proprietary multi-functional antibody R&D platform. Its pipeline includes YXC-001, a first-in-class trifunctional antibody fusion protein targeting PD-1, VEGF, and IL-2R for advanced solid tumors, and YXC-002, a fourth-generation, brain-penetrant EGFR tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC). Both candidates received Investigational New Drug (IND) approvals from the NMPA in August 2026.